Indacaterol , ≥99% , 312753-06-3
CAS NO.:312753-06-3
Empirical Formula: C24H28N2O3
Molecular Weight: 392.49
MDL number: MFCD18782702
EINECS: 691-091-1
Pack Size | Price | Stock | Quantity |
50MG | RMB619.20 | In Stock |
|
250MG | RMB1997.60 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | >165°C (dec.) |
Boiling point: | 660.3±55.0 °C(Predicted) |
Density | 1.27 |
storage temp. | -20°C Freezer, Under inert atmosphere |
solubility | DMSO (Slightly), Methanol (Slightly) |
pka | 8.68±0.20(Predicted) |
form | Solid |
color | Off-White to Light Yellow |
InChIKey | QZZUEBNBZAPZLX-QFIPXVFZSA-N |
SMILES | N1C2=C(C([C@@H](O)CNC3CC4=C(C3)C=C(CC)C(CC)=C4)=CC=C2O)C=CC1=O |
Description and Uses
Inhaled β2 adrenoceptor agonists are effective in the management of asthma and COPD, primarily through their bronchodilating properties. These drugs induce bronchodilation by causing direct relaxation of airway smooth muscle through activation of adenylate cyclase, which in turn increases intracellular cAMP levels. Indacaterol is the newest β2 agonist to reach the market. It is an ultra-long-acting agent with a duration of action suitable for once-a-day dosing. Indacaterol is supplied as an aerosol formulation of its maleate salt and is administered via a dry powder inhaler device. It is specifically approved for once-daily maintenance treatment of airflow obstruction in adult patients with COPD. In preclinical models, indacaterol is close to a full agonist at the human b2 adrenoceptor (Emax = 73 ± 1% of isoprenaline′s maximal effect, pEC50 = 8.06 ±0.02) while salmeterol displays only partial efficacy (38 ±1%). The functional selectivity profile of indacaterol over β1 human adrenoceptors is similar to that of formoterol, whereas its β3 adrenoceptor selectivity profile is similar to that of formoterol and salbutamol.
Indacaterol is a β-adrenoreceptor agonists for treatment of asthma and bronchodilator treatment for patients with chronic obstructive pulmonary diseases.
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H319-H315-H312-H332-H302-H335 |
Precautionary statements | P261-P271-P304+P340-P312-P264-P270-P301+P312-P330-P501-P264-P280-P302+P352-P321-P332+P313-P362-P280-P302+P352-P312-P322-P363-P501-P264-P280-P305+P351+P338-P337+P313P |